Immune related adverse events associated with anti-CT and meta-analysis

BMC Medicine

13, 211

DOI: 10.1186/s12916-015-0455-8

Citation Report

#	Article	IF	Citations
1	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. Translational and Clinical Pharmacology, 2016, 24, 7.	0.3	3
2	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitorsâ€”an autopsy study. , 2016, 4, 13.		162
3	Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS ONE, 2016, 11, e0160221.	1.1	373
4	Checkpoint inhibitors and gastrointestinal immune-related adverse events. Current Opinion in Oncology, 2016, 28, 264-268.	1.1	35
5	Managing Adverse Events With Immune Checkpoint Agents. Cancer Journal (Sudbury, Mass), 2016, 22, 121-129.	1.0	42
6	Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors. JAMA Oncology, 2016, 2, 1346.	3.4	667
7	How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD. Inflammatory Bowel Diseases, 2016, 22, 1262-1274.	0.9	40
8	The current status of checkpoint inhibitors in metastatic bladder cancer. Clinical and Experimental Metastasis, 2016, 33, 629-635.	1.7	11
9	Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Research, 2016, 26, 308-311.	0.6	86
10	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. ESMO Open, 2016, 1, e000032.	2.0	7
11	Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. Immunotherapy, 2016, 8, 1437-1446.	1.0	25
12	Immunotherapy of colorectal cancer: new perspectives after a long path. Immunotherapy, 2016, 8, 1281-1292.	1.0	19
13	An In Vitro Model That Predicts the Therapeutic Efficacy of Immunomodulatory Antibodies. Journal of Immunotherapy, 2016, 39, 298-305.	1.2	4
14	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Journal of Hematology and Oncology, 2016, 9, 47.	6.9	271
15	Drugs, Inflammation, and the Eye. Ocular Immunology and Inflammation, 2016, 24, 125-127.	1.0	8
16	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. BioDrugs, 2016, 30, 263-273.	2.2	22
17	Clinical Significance of Circulating CD33+CD11b+HLA-DRâ^' Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 5661-5672.	3.2	170
18	Advances in immunotherapy for melanoma. BMC Medicine, 2016, 14, 20.	2.3	111

#	Article	IF	Citations
19	Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. Drug Safety, 2016, 39, 801-821.	1.4	74
20	CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain, 2016, 139, 2923-2934.	3.7	93
21	Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy. Dermatologic Therapy, 2016, 29, 306-308.	0.8	26
22	Inmunoterapia del melanoma. Piel, 2016, 31, 649-656.	0.0	0
23	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clinical Cancer Research, 2016, 22, 4550-4555.	3.2	73
24	Management of side effects of immune checkpoint blockade by antiâ€CTLAâ€4 and antiâ€PDâ€1 antibodies in metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-681.	0.4	63
25	Nebenwirkungsmanagement bei Immunâ€Checkpointâ€Blockade durch CTLAâ€4â€ und PD1â€AntikÃ¶rper beim metastasierten Melanom. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-683.	0.4	47
26	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. BioDrugs, 2016, 30, 571-584.	2.2	93
27	Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications. CNS Drugs, 2016, 30, 1149-1168.	2.7	3
28	Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1089-1100.	2.0	61
29	Hypophysitis Secondary to Cytotoxic T-Lymphocyteâ€“Associated Protein 4 Blockade. American Journal of Pathology, 2016, 186, 3225-3235.	1.9	299
30	Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nature Communications, 2016, 7, 13193.	5.8	1,270
31	A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. , 2016, 4, 85.		18
32	Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Research, 2016, 26, 609-615.	0.6	41
33	Immune checkpoint inhibitorâ€related hypophysitis and endocrine dysfunction: clinical review. Clinical Endocrinology, 2016, 85, 331-339.	1.2	177
34	Neuromuscular complications in cancer. Journal of the Neurological Sciences, 2016, 367, 184-202.	0.3	18
35	Systemic anti-CTLA-4 and intravesical Bacilleâ€“Calmetteâ€“Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?. Medical Hypotheses, 2016, 92, 57-58.	0.8	7
36	Underlying Autoimmune Disease Is Not a Contraindication to the Use of Ipilimumab. JAMA Oncology, 2016, 2, 241.	3.4	3

#	Article	IF	Citations
37	A case of arthritis under pembrolizumab. Joint Bone Spine, 2017, 84, 243-244.	0.8	14
38	Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?. Pathology and Oncology Research, 2017, 23, 837-843.	0.9	5
39	The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. British Journal of Cancer, 2017, 116, 310-317.	2.9	141
40	Review: Immuneâ€Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis and Rheumatology, 2017, 69, 687-699.	2.9	101
41	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. Revue De Medecine Interne, 2017, 38, 513-525.	0.6	36
42	Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. Expert Opinion on Drug Safety, 2017, 16, 423-428.	1.0	8
43	Combination immunotherapy: a road map. , 2017, 5, 16.		325
44	Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature. Targeted Oncology, 2017, 12, 235-241.	1.7	40
45	Immunotherapy: a new treatment paradigm in bladder cancer. Current Opinion in Oncology, 2017, 29, 184-195.	1.1	40
46	Tremelimumab-Induced Graves Hyperthyroidism. European Thyroid Journal, 2017, 6, 167-170.	1.2	42
47	Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle and Nerve, 2017, 56, E162-E167.	1.0	18
48	Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?. European Journal of Cancer, 2017, 81, 240-241.	1.3	5
50	Immunotherapy for the treatment of breast cancer. Expert Opinion on Biological Therapy, 2017, 17, 797-812.	1.4	12
51	Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients. Melanoma Research, 2017, 27, 110-115.	0.6	10
52	Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. Science Advances, 2017, 3, e1602133.	4.7	27
53	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. Oncologist, 2017, 22, 680-693.	1.9	23
54	Immunotherapy: The Wave of the Future in Bladder Cancer?. Clinical Genitourinary Cancer, 2017, 15, S3-S17.	0.9	8
55	Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. Cancer Investigation, 2017, 35, 443-455.	0.6	67

#	Article	IF	Citations
56	Targeting Immunotherapy to the Tumor Microenvironment. Journal of Cellular Biochemistry, 2017, 118, 3049-3054.	1.2	54
57	Adverse Events in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2017, 995, 155-174.	0.8	45
58	Cancer Immunotherapy: Whence and Whither. Molecular Cancer Research, 2017, 15, 635-650.	1.5	30
59	Recognizing and managing on toxicities in cancer immunotherapy. Tumor Biology, 2017, 39, 101042831769454.	0.8	27
60	Rheumatic and Musculoskeletal Immuneâ€Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care and Research, 2017, 69, 1751-1763.	1.5	292
61	Early Immune-Related Adverse Events and Association with Outcome in Advanced Nonâ€“Small Cell Lung Cancer Patients Treated with Nivolumab: AÂProspective Cohort Study. Journal of Thoracic Oncology, 2017, 12, 1798-1805.	0.5	311
62	Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology. Seminars in Oncology Nursing, 2017, 33, 415-424.	0.7	13
63	Immuneâ€‘related adverse events during anticancer immunotherapy: Pathogenesis and management (Review). Oncology Letters, 2017, 14, 5671-5680.	0.8	54
64	Checkpoint inhibitors and the risk of infection. Expert Review of Precision Medicine and Drug Development, 2017, 2, 287-293.	0.4	3
65	Pharmacovigilance Assessment of Immuneâ€Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. Pharmacotherapy, 2017, 37, 1383-1390.	1.2	33
66	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Critical Reviews in Oncology/Hematology, 2017, 119, 1-12.	2.0	141
67	Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunological Reviews, 2017, 280, 249-279.	2.8	155
68	A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood, 2017, 130, 2410-2419.	0.6	44
69	Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2671-2682.	1.7	46
70	Nanomaterials for cancer immunotherapy. Biomaterials, 2017, 148, 16-30.	5.7	226
71	NF-Îº B c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. Cell, 2017, 170, 1096-1108.e13.	13.5	222
72	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncology, The, 2017, 18, 1261-1273.	5.1	356
74	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. Current Neurology and Neuroscience Reports, 2017, 17, 75.	2.0	15

#	Article	IF	Citations
75	Immunotherapy of cancers comes of age. Expert Review of Clinical Immunology, 2017, 13, 1001-1015.	1.3	84
76	Complications rhumatologiques de lâ€™immunothÃ©rapie anticancÃ©reuse. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314	0.6	0
77	Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles. Scientific Reports, 2017, 7, 16892.	1.6	23
78	Guillainâ€“BarrÃ© Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review. Journal of Clinical Neuromuscular Disease, 2017, 19, 80-83.	0.3	55
79	Management of Immune-Mediated Paraneoplastic Neurological Disorders. Neurology International Open, 2017, 01, E264-E274.	0.4	3
80	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. , 2017, 5, 35.		58
81	Pituitary Antibodies in an Adolescent with Secondary Adrenal Insufficiency and Turner Syndrome. Hormone Research in Paediatrics, 2017, 87, 123-129.	0.8	3
82	Cancer immunotherapy in patients with preexisting autoimmune disorders. Seminars in Immunopathology, 2017, 39, 333-337.	2.8	31
83	Immunotherapy of melanoma. European Journal of Surgical Oncology, 2017, 43, 594-603.	0.5	21
84	Regulatory T Cells: Central Concepts from Ontogeny to Therapy. Transfusion Medicine Reviews, 2017, 31, 36-44.	0.9	13
85	Vedolizumab as a successful treatment of CTLA-4â€“associated autoimmune enterocolitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1043-1046.e5.	1.5	24
86	Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review. BJR|case Reports, 2017, 3, 20160002.	0.1	1
87	Management and Supportive Care of Patients Undergoing Immunotherapy. , 2017, , .		0
88	Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 325-339.	0.8	52
89	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Frontiers in Pharmacology, 2017, 8, 730.	1.6	350
90	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy, 2017, Volume 10, 1487-1502.	1.0	12
91	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. Tumori, 2017, 103, 405-421.	0.6	52
92	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. Journal of Translational Medicine, 2017, 15, 244.	1.8	73

#	Article	IF	Citations
93	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
94	Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy. Neurologia Medico-Chirurgica, 2017, 57, 321-330.	1.0	16
95	Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review. Kidney Cancer, 2017, 1, 133-141.	0.2	9
96	PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. Oncotarget, 2017, 8, 66849-66864.	0.8	47
97	Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant. Journal of Onco-Nephrology, 2017, 1, 42-48.	0.3	21
98	Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Research, 2018, 28, 433-447.	5.7	91
99	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 222-234.	8.2	82
100	Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Current Oncology Reports, 2018, 20, 24.	1.8	35
101	A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects. Case Reports in Dermatology, 2018, 10, 1-6.	0.3	26
102	Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Research, 2018, 28, 230-236.	0.6	67
103	Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary, 2018, 21, 274-282.	1.6	25
104	The gut microbiota and immune checkpoint inhibitors. Human Vaccines and Immunotherapeutics, 2018, 14, 2178-2182.	1.4	28
105	Immunotherapy for Head and Neck Squamous Cell Carcinoma. Current Oncology Reports, 2018, 20, 22.	1.8	131
106	Clinical assessment of immune-related adverse events. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876462.	1.4	101
107	Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmunity Reviews, 2018, 17, 610-616.	2.5	91
108	Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery. Radiology Case Reports, 2018, 13, 261-264.	0.2	7
109	Predictors of Response to Immune Checkpoint Blockade. , 2018, , 525-544.		0
110	Thyroid dysfunctions secondary to cancer immunotherapy. Journal of Endocrinological Investigation, 2018, 41, 625-638.	1.8	59

#	Article	IF	Citations
111	A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model. Cell Reports, 2018, 22, 1-7.	2.9	42
112	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. OncoImmunology, 2018, 7, e1421891.	2.1	57
113	Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy. , 2018, , 143-152.		1
114	Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities. OncoImmunology, 2018, 7, e1466019.	2.1	4
115	CHECKPOINT INHIBITOR IMMUNE THERAPY. Retina, 2018, 38, 1063-1078.	1.0	252
116	Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflammatory Bowel Diseases, 2018, 24, 1695-1705.	0.9	177
117	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
118	Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma. Melanoma Research, 2018, 28, 171-184.	0.6	18
119	Metaâ€Analysis of the Risk of Immuneâ€Related Adverse Events With Anticytotoxic Tâ€Lymphocyteâ€Associated Antigen 4 and Antiprogrammed Death 1 Therapies. Clinical Pharmacology and Therapeutics, 2018, 103, 318-331.	2.3	22
120	Neurological complications of new chemotherapy agents. Neuro-Oncology, 2018, 20, 24-36.	0.6	28
121	Toxicity profiles of immunotherapy. , 2018, 181, 91-100.		55
122	Autoimmune Encephalitis in Children. Journal of Pediatric Neurology, 2018, 16, 192-201.	0.0	1
123	Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. Journal of Dermatological Science, 2018, 89, 60-66.	1.0	52
124	Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. European Journal of Internal Medicine, 2018, 47, 6-13.	1.0	52
125	Review of cancer treatment with immune checkpoint inhibitors. Wiener Klinische Wochenschrift, 2018, 130, 85-91.	1.0	102
126	Evolution of early phase clinical trials in oncology. Journal of Molecular Medicine, 2018, 96, 31-38.	1.7	13
127	Activation of thyroid antigen-reactive B cells in recent onset autoimmune thyroid disease patients. Journal of Autoimmunity, 2018, 89, 82-89.	3.0	36
128	Pharmacokinetics and Pharmacodynamics of Immunotherapy. Current Cancer Research, 2018, , 29-67.	0.2	6

#	Article	IF	Citations
129	Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancerâ€"clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Annals of the Rheumatic Diseases, 2018, 77, 393-398.	0.5	230
131	New Molecular, Biological, and Immunological Agents Inducing Hypophysitis. Neuroendocrinology, 2018, 106, 89-100.	1.2	14
132	Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 13-19.	1.8	74
133	First Report of Parkinsonism Associated With Indoximod, an Immune-Modulating Agent. Journal of Global Oncology, 2018, 4, 1-2.	0.5	6
134	Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies. Melanoma Management, 2018, 5, MMT07.	0.1	15
135	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine, 2018, 24, 1804-1808.	15.2	521
137	Small Cell Lung Cancer with Sarcoidosis in Spontaneous Remission: A Case Report. Journal of Nippon Medical School, 2018, 85, 291-296.	0.3	3
138	Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review. Current Oncology, 2018, 25, 342-347.	0.9	98
139	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. Cell Reports, 2018, 25, 3564-3572.e4.	2.9	49
140	Strategies of Combination Drug Delivery for Immune Checkpoint Blockades. Advanced Healthcare Materials, 2019, 8, e1801099.	3.9	32
142	Thyroid disorders induced by checkpoint inhibitors. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 325-333.	2.6	87
144	The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function. Cell Reports, 2018, 25, 80-94.	2.9	60
145	Immune Checkpoint Inhibitorâ€"Associated Myositis. Circulation, 2018, 138, 743-745.	1.6	139
147	Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. European Journal of Cancer, 2018, 104, 239-242.	1.3	43
148	Immunoengineering through cancer vaccines â€" A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release, 2018, 289, 125-145.	4.8	31
149	A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. , 2018, 6, 90.		32
150	A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. Journal of Autoimmunity, 2018, 95, 77-99.	3.0	141
151	Rheumatic immune-related adverse events from cancer immunotherapy. Nature Reviews Rheumatology, 2018, 14, 569-579.	3.5	162

#	Article	IF	Citations
152	Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy. Cellular Physiology and Biochemistry, 2018, 47, 721-734.	1.1	131
153	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. Journal of Pain and Symptom Management, 2018, 56, 460-472.	0.6	14
154	Goodpastureâ€™s disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report. Lung Cancer, 2018, 122, 22-24.	0.9	29
155	Cutaneous CD56 + T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma. JAAD Case Reports, 2018, 4, 540-542.	0.4	12
156	Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes, 2018, 67, 1471-1480.	0.3	386
157	Ipilimumab treatment associated with myasthenic crises and unfavorable disease course. Neurological Sciences, 2018, 39, 1773-1774.	0.9	11
158	Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2018, 168, 121.	2.0	341
159	Immune Checkpoint Inhibitor Toxicity. Current Oncology Reports, 2018, 20, 72.	1.8	91
160	Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2075-2082.	1.3	6
161	New Immunotherapies in Oncology Treatment and Their Side Effect Profiles. Journal of the American Board of Family Medicine, 2018, 31, 620-627.	0.8	7
162	Sclerodermaâ€like skin changes induced by checkpoint inhibitor therapy. Journal of Cutaneous Pathology, 2018, 45, 615-618.	0.7	51
163	Bakerâ€™s yeast induces apoptotic effects and histopathological changes on skin tumors in mice. Cogent Medicine, 2018, 5, 1437673.	0.7	3
164	Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. Journal of Emergency Medicine, 2018, 55, 489-502.	0.3	58
165	Autologous graft-versus-host disease with combined immune checkpoint blockade. European Journal of Cancer, 2018, 101, 275-277.	1.3	0
166	Optic Neuritis Possibly Induced by Anti-PD-L1 Antibody Treatment in a Patient with Non-Small Cell Lung Carcinoma. Case Reports in Ophthalmology, 2018, 9, 348-356.	0.3	25
167	Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmunity Reviews, 2018, 17, 1040-1045.	2.5	66
168	Increased frequency of acute reactions to iodinated contrast media in cancer patients treated with anti-CTLA-4 immunomodulatory antibodies. Medical Hypotheses, 2018, 119, 26-28.	0.8	3
169	Immune-Related Adverse Toxicities and Clinical Management. , 2018, , 577-589.		0

#	Article	IF	Citations
170	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Seminars in Arthritis and Rheumatism, 2019, 48, 736-740.	1.6	90
171	Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor Î± therapy. Journal of Oncology Pharmacy Practice, 2019, 25, 1275-1281.	0.5	14
172	Cancer immunotherapy-associated hypophysitis. Future Oncology, 2019, 15, 3159-3169.	1.1	24
173	Immune therapy, a double-edged sword for oncolytic viruses. Expert Opinion on Biological Therapy, 2019, 19, 1111-1113.	1.4	1
174	Serious immuneâ€related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head and Neck, 2019, 41, 4036-4050.	0.9	3
175	A Review of Immune-Mediated Adverse Events in Melanoma. Oncology and Therapy, 2019, 7, 101-120.	1.0	23
176	Clinical significance of signs of autoimmune colitis in ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy, 2019, 11, 667-676.	1.0	41
177	Drug Effects on the Thyroid. New England Journal of Medicine, 2019, 381, 749-761.	13.9	98
178	To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. Cancer, 2019, 125, 3506-3513.	2.0	24
179	Immune-Related Adverse Events: A Case-Based Approach. Frontiers in Oncology, 2019, 9, 530.	1.3	31
180	Macroangiopathy is a positive predictive factor for response to immunotherapy. Scientific Reports, 2019, 9, 9728.	1.6	6
181	Hepatotoxicity of immune check point inhibitors: Approach and management. Digestive and Liver Disease, 2019, 51, 1074-1078.	0.4	32
182	Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. , 2019, 7, 165.		135
183	Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer. Drugs and Aging, 2019, 36, 927-938.	1.3	74
184	The Changing Clinical Spectrum of Hypophysitis. Trends in Endocrinology and Metabolism, 2019, 30, 590-602.	3.1	35
185	Vitiligo-Like Lesions in Patients with Metastatic Melanoma Receiving Immunotherapies. , 2019, , 163-167.		0
186	Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. Melanoma Management, 2019, 6, MMT13.	0.1	13
187	Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocrine Journal, 2019, 66, 581-586.	0.7	63

#	Article	IF	Citations
188	Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis . Drug Design, Development and Therapy, 2019, Volume 13, 2215-2234.	2.0	20
189	Immunotherapy of brain metastases: breaking a â€œdogmaâ€• Journal of Experimental and Clinical Cancer Research, 2019, 38, 419.	3.5	70
190	Exploiting autoimmunity unleashed by lowâ€dose immune checkpoint blockade to treat advanced cancer. Scandinavian Journal of Immunology, 2019, 90, e12821.	1.3	20
191	Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Critical Reviews in Oncology/Hematology, 2019, 143, 139-147.	2.0	100
192	Physical and chemical profiles of nanoparticles for lymphatic targeting. Advanced Drug Delivery Reviews, 2019, 151-152, 72-93.	6.6	79
193	The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus. Cells, 2019, 8, 1213.	1.8	14
194	Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 Medicine Research, 2019, 11, 225-236.	0.6	133
195	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. Journal of Oncology Practice, 2019, 15, e825-e834.	2.5	37
196	Integrin-Mediated TGFÎ² Activation Modulates the Tumour Microenvironment. Cancers, 2019, 11, 1221.	1.7	62
197	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Seminars in Cancer Biology, 2019, 59, 290-297.	4.3	78
198	Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Scientific Reports, 2019, 9, 14039.	1.6	125
199	Immune checkpoint inhibitorâ€“related luminal GI adverseÂevents. Gastrointestinal Endoscopy, 2019, 90, 881-892.	0.5	24
200	Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer. Internal Medicine, 2019, 58, 3557-3562.	0.3	14
201	Nanoparticleâ€Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy. Advanced Materials, 2019, 31, e1802228.	11.1	448
202	Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80Âyears) treated with ipilimumab for metastatic melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 545-551.	2.0	18
203	Advancing Cancer Immunotherapies with Nanotechnology. Advanced Therapeutics, 2019, 2, 1800128.	1.6	45
204	Immunotherapy Toxicity. Hematology/Oncology Clinics of North America, 2019, 33, 275-290.	0.9	23
205	‹p›Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis‹/p›. Cancer Management and Research, 2019, Volume 11, 5209-5220.	0.9	14

#	Article	IF	Citations
206	Recent perspective on CAR and FcÎ³-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes. Biochemical Pharmacology, 2019, 166, 335-346.	2.0	20
207	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Medicine, 2019, 45, 988-997.	3.9	18
208	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. , 2019, 7, 142.		31
209	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences, 2019, 20, 2560.	1.8	72
211	The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. BMC Cancer, 2019, 19, 559.	1.1	62
212	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer, 2019, 19, 558.	1.1	106
213	Molecular and immune targets for Merkel cell carcinoma therapy and prevention. Molecular Carcinogenesis, 2019, 58, 1602-1611.	1.3	5
214	MiStImm: an agent-based simulation tool to study the self-nonself discrimination of the adaptive immune response. Theoretical Biology and Medical Modelling, 2019, 16, 9.	2.1	1
215	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology, 2019, 16, 563-580.	12.5	1,235
216	Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis. Progress in Retinal and Eye Research, 2019, 72, 100761.	7.3	37
217	Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106.		203
218	Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Letters, 2019, 456, 80-87.	3.2	36
219	Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department. Emergency Medicine Journal, 2019, 36, 306-309.	0.4	16
220	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunology, Immunotherapy, 2019, 68, 897-905.	2.0	38
221	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Hormone and Metabolic Research, 2019, 51, 145-156.	0.7	234
222	The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. , 2019, 7, 103.		79
223	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	3.5	170
225	Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis. Journal of Cancer, 2019, 10, 120-130.	1.2	5

#	Article	IF	Citations
226	Cardiac Complications in Immune Checkpoint Inhibition Therapy. Frontiers in Cardiovascular Medicine, 2019, 6, 3.	1.1	65
227	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clinical Pharmacokinetics, 2019, 58, 835-857.	1.6	222
228	Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-12.	0.8	43
229	Toxicity of tumor immune checkpoint inhibitorsâ€"more attention should be paid. Translational Lung Cancer Research, 2019, 8, 1125-1133.	1.3	7
230	Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy. Theranostics, 2019, 9, 8332-8343.	4.6	31
231	Impaired Bâ€€cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunological Reviews, 2019, 292, 90-101.	2.8	86
232	Immune-Mediated Colitis. Current Treatment Options in Gastroenterology, 2019, 17, 506-523.	0.3	6
233	Data Mining of Prognostic Microenvironment-Related Genes in Clear Cell Renal Cell Carcinoma: A Study with TCGA Database. Disease Markers, 2019, 2019, 1-11.	0.6	25
234	Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. Journal of Immunotherapy, 2019, 42, 348-349.	1.2	4
235	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nature Communications, 2019, 10, 5546.	5.8	98
236	Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment. Medicine (United States), 2019, 98, e16158.	0.4	8
237	Toxicities associated with checkpoint inhibitorsâ€"an overview. Rheumatology, 2019, 58, vii7-vii16.	0.9	80
238	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist, 2019, 24, 735-742.	1.9	43
239	Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?. Inflammatory Bowel Diseases, 2019, 25, 385-393.	0.9	63
240	Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. European Journal of Cancer, 2019, 107, 8-14.	1.3	127
241	Identification of discrepancy between CTLA4 expression and CTLA4 activation in gastric cancer. Immunopharmacology and Immunotoxicology, 2019, 41, 386-393.	1.1	27
242	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunology Research, 2019, 7, 6-11.	1.6	118
243	Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy. Clinical Rheumatology, 2019, 38, 601-602.	1.0	17

#	Article	IF	Citations
244	Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors. Case Reports in Gastroenterology, 2019, 12, 704-708.	0.3	8
245	Multi-faceted inhibition of dendritic cell function by CD4+Foxp3+ regulatory T cells. Journal of Autoimmunity, 2019, 98, 86-94.	3.0	7
246	Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. Journal of Oncology Pharmacy Practice, 2019, 25, 1867-1872.	0.5	5
247	Tipping the balance: inhibitory checkpoints in intestinal homeostasis. Mucosal Immunology, 2019, 12, 21-35.	2.7	13
248	Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Modern Rheumatology, 2019, 29, 721-732.	0.9	10
249	Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. International Journal of Clinical Oncology, 2019, 24, 1508-1514.	1.0	13
250	Comment on: Thymectomy in patients with myasthenia gravis increases the risk of autoimmune rheumatic diseases: a nationwide cohort study. Rheumatology, 2020, 59, 451-452.	0.9	0
251	Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Modern Pathology, 2020, 33, 99-108.	2.9	64
252	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians ShouldÂKnow. Annals of Emergency Medicine, 2020, 75, 264-286.	0.3	3
253	Targeting B7â€1 in immunotherapy. Medicinal Research Reviews, 2020, 40, 654-682.	5.0	44
254	Biomarkers for immune checkpoint inhibition in nonâ€“small cell lung cancer (NSCLC). Cancer, 2020, 126, 260-270.	2.0	202
255	TGF-Î²1 â€“ A truly transforming growth factor in fibrosis and immunity. Seminars in Cell and Developmental Biology, 2020, 101, 123-139.	2.3	264
256	Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. European Journal of Medicinal Chemistry, 2020, 186, 111876.	2.6	98
257	Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Journal of Immunotherapy, 2020, 43, 1-7.	1.2	75
258	New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101370.	2.2	60
259	Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges. Life Sciences, 2020, 240, 117093.	2.0	12
260	Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors. Journal of Immunotherapy, 2020, 43, 67-74.	1.2	14
261	Structure and Optimization of Checkpoint Inhibitors. Cancers, 2020, 12, 38.	1.7	37

#	Article	IF	Citations
262	Neurological immuneâ€related adverse events associated with immune checkpoint inhibitors: A review of the literature. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 291-298.	0.7	21
263	Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics. Accounts of Chemical Research, 2020, 53, 2521-2533.	7.6	81
264	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. Vaccines, 2020, 8, 578.	2.1	16
265	Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 11725-11740.	1.0	25
266	Genomic profiling of T-cell activation suggests increased sensitivity of memory T cells to CD28 costimulation. Genes and Immunity, 2020, 21, 390-408.	2.2	17
267	Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy. Materials Today Bio, 2020, 8, 100082.	2.6	18
268	Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review . Eye and Brain, 2020, Volume 12, 139-167.	3.8	28
269	Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. Expert Review of Clinical Immunology, 2020, 16, 771-785.	1.3	10
270	Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study. BMC Cancer, 2020, 20, 743.	1.1	18
271	Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. International Journal of Radiation Oncology Biology Physics, 2020, 108, 242-257.	0.4	8
272	Sarcoidosis-like disease mimicking metastases during adjuvant ipilimumab therapy in advanced melanoma patient: CT scan and MRI help in managing difficult clinical decision. BJR|case Reports, 2020, 6, 20190065.	0.1	5
273	Rheumatic immuneâ€related adverse events induced by immune checkpoint inhibitors. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 178-185.	0.7	17
274	Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction. Annals of Translational Medicine, 2020, 8, 889-889.	0.7	2
275	Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses. Frontiers in Immunology, 2020, 11, 584680.	2.2	8
276	Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies. Autoimmunity Reviews, 2020, 19, 102687.	2.5	35
277	Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Frontiers in Immunology, 2020, 11, 2023.	2.2	50
278	Imaging findings of immune checkpoint inhibitor associated pancreatitis. European Journal of Radiology, 2020, 131, 109250.	1.2	24
279	Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases. Autoimmunity Reviews, 2020, 19, 102658.	2.5	9

#	Article	IF	Citations
280	Immune Related Adverse Events. Cancer Journal (Sudbury, Mass), 2020, 26, 432-440.	1.0	4
282	64-Year-Old Man With Altered Mental Status. Mayo Clinic Proceedings, 2020, 95, e91-e96.	1.4	1
283	New-onset gravesâ€™ disease after the initiation of nivolumab therapy for gastric cancer: a case report. BMC Endocrine Disorders, 2020, 20, 132.	0.9	11
284	Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis. Drug Safety, 2020, 43, 1255-1266.	1.4	5
285	Evaluation of Checkpoint Inhibitors in Cancer Patients With End-stage Renal Disease on Hemodialysis: Case Series and Review of the Literature. Journal of Immunotherapy, 2020, 43, 244-249.	1.2	12
286	Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy . International Journal of Nanomedicine, 2020, Volume 15, 5279-5288.	3.3	18
287	The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. Journal of Experimental and Clinical Cancer Research, 2020, 39, 284.	3.5	67
288	Living with Metastatic Cancer: A Roadmap for Future Research. Cancers, 2020, 12, 3684.	1.7	26
289	Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease. , 2020, 8, e001627.		8
290	Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. Pharmaceutics, 2020, 12, 1054.	2.0	77
291	Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. Western Journal of Emergency Medicine, 2020, 21, 566-580.	0.6	13
292	Targeting Inhibition of Foxp3 by MMP2/9 Sensitive Short Peptide Linked P60 Fusion Protein 6(P60â€MMPs) to Enhance Antitumor Immunity. Macromolecular Bioscience, 2020, 20, 2000098.	2.1	5
293	Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e275-e291.	1.8	32
294	Immune checkpoint signaling and cancer immunotherapy. Cell Research, 2020, 30, 660-669.	5.7	617
295	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. The Lancet Gastroenterology and Hepatology, 2020, 5, 679-697.	3.7	33
296	Control of foreign Agâ€specific Ab responses by Treg and Tfr. Immunological Reviews, 2020, 296, 104-119.	2.8	40
297	Side effect management during immune checkpoint blockade using CTLAâ€4 and PDâ€1 antibodies for metastatic melanoma â€“ an update. JDDG - Journal of the German Society of Dermatology, 2020, 18, 582-609.	0.4	24
298	Hypophysitis (Including IgG4 and Immunotherapy). Neuroendocrinology, 2020, 110, 822-835.	1.2	21

#	Article	IF	Citations
299	Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. Clinical Immunology, 2020, 213, 108377.	1.4	44
300	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. Journal of Biosciences, 2020, 45, 1.	0.5	24
301	Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 546.	1.7	177
302	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. Seminars in Nuclear Medicine, 2020, 50, 518-531.	2.5	25
303	Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. OncoImmunology, 2020, 9, 1748982.	2.1	23
304	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. Journal of Clinical Medicine, 2020, 9, 2033.	1.0	13
305	Immune Checkpoint Inhibitionâ€"Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. Rheumatic Disease Clinics of North America, 2020, 46, 587-603.	0.8	3
306	Intratumoral Nanofluidic System for Enhancing Tumor Biodistribution of Agonist CD40 Antibody. Advanced Therapeutics, 2020, 3, 2000055.	1.6	12
307	Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) â€" protocol for a multi-center, single-arm phase IIa trial. Contemporary Clinical Trials Communications, 2020, 19, 100575.	0.5	10
308	Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nature Reviews Clinical Oncology, 2020, 17, 313-326.	12.5	60
309	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 91.	1.3	112
310	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. Oncologist, 2020, 25, 290-300.	1.9	51
311	A review of cancer immunotherapy toxicity. Ca-A Cancer Journal for Clinicians, 2020, 70, 86-104.	157.7	753
312	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 320-341.	1.8	165
313	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. Nature Immunology, 2020, 21, 199-209.	7.0	68
314	Cancer immunotherapy: Current applications and challenges. Cancer Letters, 2020, 480, 1-3.	3.2	19
315	Autoimmune complications of immunotherapy: pathophysiology and management. BMJ, The, 2020, 369, m736.	3.0	79
316	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. , 2020, 8, e000371.		14

#	Article	IF	Citations
317	Combination Immunotherapy with Cytotoxic T-Lymphocyteâ€“Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis. Molecular Cancer Therapeutics, 2020, 19, 802-811.	1.9	18
318	Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect. BMC Cancer, 2020, 20, 300.	1.1	25
319	Advances on immune-related adverse events associated with immune checkpoint inhibitors. Frontiers of Medicine, 2021, 15, 33-42.	1.5	24
320	Improving safety of cancer immunotherapy via delivery technology. Biomaterials, 2021, 265, 120407.	5.7	22
321	Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. Cellular and Molecular Immunology, 2021, 18, 919-935.	4.8	11
322	Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. Radiographics, 2021, 41, 120-143.	1.4	27
323	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160.	2.0	26
324	Analysis of Risk Factors for Hepatotoxicity Induced by Immune Checkpoint Inhibitors. Journal of Immunotherapy, 2021, 44, 16-21.	1.2	17
325	CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumorâ€specific therapies. Abdominal Radiology, 2021, 46, 2219-2235.	1.0	14
326	Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine. , 2021, , 109-134.		0
327	Toxicities of Novel Antineoplastic Therapies. , 2021, , 711-738.		1
328	Review of immune checkpoint inhibitors in immuno-oncology. Advances in Pharmacology, 2021, 91, 111-139.	1.2	43
329	Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1. Reviews on Recent Clinical Trials, 2021, 15, 339-346.	0.4	5
330	Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. MedComm, 2021, 2, 175-206.	3.1	24
331	Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Review of Clinical Pharmacology, 2021, 14, 179-210.	1.3	8
332	Ipilimumab in Melanoma: An Evergreen Drug. , 2021, , 217-235.		0
333	Nanotechnology for Diagnosis, Imaging, and Treatment of Head and Neck Cancer. , 2021, , 63-120.		1
334	The PD-1:PD-L1 axis in Inflammatory Arthritis. BMC Rheumatology, 2021, 5, 1.	0.6	29

#	Article	IF	Citations
335	Fcî³ receptorsâ€"Master regulators of antibody therapy. , 2021, , 195-225.		0
336	Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritis. , 2021, , 273-291.		0
337	A case of autoimmune enteropathy with CTLA4 haploinsufficiency. Intestinal Research, 2022, 20, 144-149.	1.0	6
338	Comorbidity and frailty assessment in renal cell carcinoma patients. World Journal of Urology, 2021, 39, 2831-2841.	1.2	7
339	Gastrointestinal motility disorders in neurologic disease. Journal of Clinical Investigation, 2021, 131, .	3.9	68
340	Pituitary enlargement following ipilimumab without long term endocrine dysfunction. Current Problems in Cancer, 2021, 45, 100710.	1.0	1
341	Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers, 2021, 13, 584.	1.7	6
342	Mapping Out Autoimmunity Control in Primary Immune Regulatory Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 653-659.	2.0	3
343	Guillain-BarrÃ© Syndrome Developed as a Neurological Immune-related Adverse Event After Response to Combination Chemo-immunotherapy. Japanese Journal of Lung Cancer, 2021, 61, 24-29.	0.0	1
344	Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. Frontiers in Immunology, 2021, 12, 616837.	2.2	72
345	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. Nanomaterials, 2021, 11, 661.	1.9	23
347	Translational Research in Vitiligo. Frontiers in Immunology, 2021, 12, 624517.	2.2	22
348	Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance. Biomedicines, 2021, 9, 304.	1.4	16
349	Immune Checkpoint Inhibitors in the Treatment of Cancer. Current Clinical Pharmacology, 2022, 17, 103-113.	0.2	18
350	Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces. Expert Opinion on Biological Therapy, 2021, 21, 1097-1120.	1.4	5
351	Adverse events induced by immune checkpoint inhibitors. Current Opinion in Immunology, 2021, 69, 29-38.	2.4	25
352	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Journal of Experimental and Clinical Cancer Research, 2021, 40, 172.	3.5	104
353	Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort. Cancers, 2021, 13, 2200.	1.7	10

#	Article	IF	Citations
354	Atezolizumab-induced Autoimmune Diabetes in a Patient with Metastatic Breast Cancer: A Case Report. Clinical Practice and Cases in Emergency Medicine, 2021, 2, 190-193.	0.1	5
355	Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e483-e487.	0.2	1
356	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. International Journal of Molecular Sciences, 2021, 22, 5801.	1.8	182
357	Immunotherapy for Breast Cancer Treatment. Iranian Biomedical Journal, 2021, 25, 140-156.	0.4	2
359	Diet, Microbiome, and Cancer Immunotherapyâ€"A Comprehensive Review. Nutrients, 2021, 13, 2217.	1.7	42
361	The dark side of immunotherapy. Annals of Translational Medicine, 2021, 9, 1041-1041.	0.7	12
362	Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Annals of Translational Medicine, 2021, 9, 1033-1033.	0.7	23
363	Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis. Frontiers in Oncology, 2021, 11, 693321.	1.3	16
364	Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. Cancer Letters, 2021, 509, 53-62.	3.2	13
365	Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. Lung Cancer Management, 2021, 10, LMT51.	1.5	10
366	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 1244-1256.	0.9	4
367	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research, 2021, 27, 5280-5288.	3.2	21
368	Hypothalamicâ€"Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. Cancers, 2021, 13, 4036.	1.7	3
369	Cancer treatment-related cardiovascular disease: Current status and future research priorities. Biochemical Pharmacology, 2021, 190, 114599.	2.0	14
370	Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitorâ€"Related Esophagitis. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 896-904.	2.3	13
371	Immune Checkpoint Inhibitors and Neurotoxicity. Current Neuropharmacology, 2021, 19, 1246-1263.	1.4	10
372	Immune PET Imaging. Radiologic Clinics of North America, 2021, 59, 875-886.	0.9	2
373	Pharmacologically induced uveitis. Survey of Ophthalmology, 2021, 66, 781-801.	1.7	6

#	Article	IF	Citations
374	Leveraging the Treg-intrinsic CTLA4â€“PKCÎ· signaling pathway for cancer immunotherapy. , 2021, 9, e002792.		2
375	Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules, 2021, 26, 5789.	1.7	23
376	Immune checkpoint inhibitors: An emergency medicine focused review. American Journal of Emergency Medicine, 2021, 50, 335-344.	0.7	5
377	Atezolizumab-induced bilateral anterior uveitis: A case report. American Journal of Ophthalmology Case Reports, 2021, 24, 101205.	0.4	2
378	Local immunotherapy of cancer and metastasis. , 2022, , 483-528.		1
379	Proteomic biomarker technology for cancer immunotherapy. , 2022, , 357-397.		0
380	Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232097699.	1.1	12
381	Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 1939-1949.	2.0	27
382	Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies. Methods in Molecular Biology, 2020, 2055, 93-117.	0.4	4
384	Challenges of Immunotherapy. , 2016, , 419-434.		1
385	Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1932-1943.	3.3	17
386	Hypophysitis. , 2019, , 325-338.		3
387	Immune checkpoint inhibitorâ€“associated hypercalcaemia. Nephrology Dialysis Transplantation, 2022, 37, 1598-1608.	0.4	12
389	Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-BarrÃ© syndrome. BMJ Case Reports, 2017, 2017, bcr-2017-221318.	0.2	6
390	Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder. Journal of Clinical Investigation, 2020, 130, 5551-5561.	3.9	18
391	Imaging of tumour response to immunotherapy. European Radiology Experimental, 2020, 4, 2.	1.7	65
392	Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management. Clinical Journal of Oncology Nursing, 2017, 21, 45-52.	0.3	22
393	A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.. Journal of Clinical Oncology, 2013, 31, 9079-9079.	0.8	7

#	Article	IF	Citations
394	Immunotherapyâ€Induced Colitis: An Emerging Problem for the Hospitalist. Journal of Hospital Medicine, 2018, 13, 413-418.	0.7	25
395	Development, evaluation, and validation of machine learning models for COVID-19 detection based on routine blood tests. Clinical Chemistry and Laboratory Medicine, 2021, 59, 421-431.	1.4	109
396	Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. Endocrine Connections, 2020, 9, 318-325.	0.8	23
397	Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocrine Connections, 2020, 9, R207-R228.	0.8	66
398	Management of Immunotherapy Related Adverse Effects. Journal of Cancer Prevention & Current Research, 2016, 6, .	0.1	1
399	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview. Current Drug Safety, 2019, 14, 14-20.	0.3	34
400	Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. Immunotherapy, 2020, 12, 481-510.	1.0	7
401	Adverse effects of immuno-oncology drugsâ€"Awareness, diagnosis, and management: A literature review of immune-mediated adverse events. Indian Journal of Cancer, 2019, 56, 10.	0.2	3
402	Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders. Journal of Immunotherapy and Precision Oncology, 2019, 2, 59-64.	0.6	8
403	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World Journal of Gastrointestinal Pathophysiology, 2019, 10, 17-28.	0.5	26
404	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 255-289.	2.3	393
405	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	2.3	326
406	Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1191-1199.	2.3	27
407	Immunotherapy Outcomes in Advanced Melanoma in Relation to Age. , 2020, 24, .		8
408	Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1415-1424.	2.3	10
409	Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors. Archives of Medical Research, 2022, 53, 113-121.	1.5	2
410	Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer. Cancer, 2022, 128, 819-827.	2.0	3
411	Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity. Frontiers in Medicine, 2021, 8, 756870.	1.2	2

#	Article	IF	Citations
412	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. European Journal of Cancer, 2021, 157, 474-484.	1.3	45
413	Immune Checkpoint Inhibition. , 2018, , 315-353.		0
414	Current Challenges and Applications of Oncolytic Viruses in Overcoming the Development of Resistance to Therapies in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 63-96.	0.1	0
415	å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³è–¬ã•å¿ƒè‡“æœ‰å®³äº‹è±¡. Journal of JCS Cardiologists, 2019, 28, 3-9.	0.1	2
416	Hypothyroidism and Hashimotoâ€™s Thyroiditis: Mechanisms, Diagnosis, Neuropsychological Phenotypes, and Treatments. , 2019, , 549-579.		0
417	Experiencia clÃnica con ipilimumab en el tratamiento de melanoma metastÃ¡sico o irresecable en el Instituto Nacional de CancerologÃa, BogotÃ¡, Colombia : serie de casos.. Revista Colombiana De HematologÃa Y OncologÃa, 2019, 6, 10-17.	0.0	0
418	The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types. Journal of the Advanced Practitioner in Oncology, 2019, 10, 367-386.	0.2	0
419	Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 435-443.	0.8	5
421	Immune-related adverse events associated with cancer immunotherapy. Practical Oncology, 2019, 2, 24-44.	0.1	0
423	Systems Immunology Approach in Understanding the Association of Allergy and Cancer. , 2020, , 53-72.		0
424	THE RELATIONSHIP BETWEEN OF CANCERS AND RHEUMATIC DISEASES. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 198-206.	0.2	0
428	Side effects and management in immunotherapy based on immune checkpoint inhibitors. World Chinese Journal of Digestology, 2020, 28, 755-764.	0.0	1
429	Nivolumab dose escalation triggered immune checkpoint inhibitor-induced colitis after 147 weeks of prolonged stable use in a patient with lung cancer: a case report. Clinical Journal of Gastroenterology, 2022, 15, 128-133.	0.4	4
430	Immune checkpoint inhibitor myocarditis: a systematic case study. Russian Journal of Cardiology, 2020, 25, 3910.	0.4	6
431	Genomics and Bioinformatics in Biological Discovery and Pharmaceutical Development. , 2020, , 105-142.		1
432	Autoimmune Hypophysitis. , 2020, , 815-830.		0
434	A Novel Human Recombinant Lactoferrin Inhibits Lung Adenocarcinoma Cell Growth and Migration with No Cytotoxic Effect on Normal Human Epithelial Cells. Archivum Immunologiae Et Therapiae Experimentalis, 2021, 69, 33.	1.0	9
435	Risk factors for immune-related adverse events: what have we learned and what lies ahead?. Biomarker Research, 2021, 9, 79.	2.8	36

#	Article	IF	Citations
436	Circulating predictive markers of immune checkpoint inhibitors in non-small cell lung cancer. Uspehi Molekularnoj Onkologii, 2021, 8, 34-43.	0.1	0
437	Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis. Translational Cancer Research, 2020, 9, 4173-4187.	0.4	2
438	Prospects of Cell Immobilization in Cancer Research and Immunotherapy. Gels Horizons: From Science To Smart Materials, 2021, , 165-193.	0.3	0
441	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clinical Advances in Hematology and Oncology, 2017, 15, 466-477.	0.3	3
442	Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. Gastroenterology and Hepatology, 2021, 17, 358-366.	0.2	3
443	Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. MAbs, 2021, 13, 2004638.	2.6	15
444	The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. Trends in Endocrinology and Metabolism, 2022, 33, 87-104.	3.1	11
445	Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study. Frontiers in Endocrinology, 2021, 12, 809063.	1.5	0
446	Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients. Supportive Care in Cancer, 2022, 30, 3613-3623.	1.0	5
447	Peripheral immunophenotyping of AITD subjects reveals alterations in immune cells in pediatric vs adult-onset AITD. IScience, 2022, 25, 103626.	1.9	5
448	Vectorized Treg-depleting Î±CTLA-4 elicits antigen cross-presentation and CD8⁺ T cell immunity to reject â€˜coldâ€™ tumors. , 2022, 10, e003488.		14
449	Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy. Cancer Treatment and Research Communications, 2022, 31, 100529.	0.7	1
450	PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model. International Immunopharmacology, 2022, 105, 108551.	1.7	4
451	A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre. Current Oncology, 2022, 29, 869-880.	0.9	2
452	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. Journal of Biosciences, 2020, 45, .	0.5	6
453	Neurologic complications of immune modulatory therapy. , 2022, , 537-551.		0
454	Differential diagnosis of pituitary enlargement. Vnitrni Lekarstvi, 2022, 68, 58-63.	0.1	0
455	Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Seminars in Cancer Biology, 2022, 86, 909-922.	4.3	26

#	Article	IF	Citations
456	Ultrasound-controllable engineered bacteria for cancer immunotherapy. Nature Communications, 2022, 13, 1585.	5.8	78
457	Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology, 2022, 75, 1604-1626.	3.6	97
458	Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. Cancer Biology and Medicine, 2021, 18, 1118-1133.	1.4	16
459	Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. Experimental Cell Research, 2022, 416, 113157.	1.2	15
461	Immunology of tissue homeostasis, ovarian cancer growth and regression, and long lasting cancer immune prophylaxis - review of literature. Histology and Histopathology, 2021, 36, 31-46.	0.5	0
464	Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. Theranostics, 2022, 12, 3719-3746.	4.6	23
465	A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events. Internal Medicine, 2022, , .	0.3	4
466	Assessment of the Novel, Practical, and Prognosis-Relevant TNM Staging System for Stage I-III Cutaneous Melanoma. Frontiers in Oncology, 2022, 12, 738298.	1.3	1
467	Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123483119.	3.3	0
468	Immune checkpoint inhibitor-related hypophysitis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101668.	2.2	11
469	Hyaluronidase Enhances Targeting of Hydrogel-Encapsulated Anti-CTLA-4 to Tumor Draining Lymph Nodes and Improves Anti-Tumor Efficacy. Gels, 2022, 8, 284.	2.1	3
470	Skin manifestations associated with checkpoint inhibitors. , 2022, 1, 73-87.		3
471	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. Cancers, 2022, 14, 2460.	1.7	2
472	FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. Seminars in Nuclear Medicine, 2022, 52, 707-719.	2.5	10
473	Immunotherapy toxicities: An SGO clinical practice statement. Gynecologic Oncology, 2022, , .	0.6	1
474	Rheumatoid Arthritis Symptoms Diagnosed by Rheumatic Immune-related Adverse Events Caused by Nivolumab in a Patient with Esophageal Cancer: A Case Report. Internal Medicine, 2022, , .	0.3	1
475	The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis. Medicina (Lithuania), 2022, 58, 768.	0.8	1
476	IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy. Biomarker Research, 2022, 10, .	2.8	2

#	Article	IF	Citations
477	Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition). Liver Cancer, 2022, 11, 511-526.	4.2	11
478	Immunotherapy-induced Hepatotoxicity: A Review. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	3
479	Research Progress Based on Regulation of Tumor Microenvironment Redox and Drug-Loaded Metal-Organic Frameworks. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-12.	1.9	1
480	TNF-Î± inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice. Frontiers in Immunology, 0, 13, .	2.2	4
481	Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment. , 0, , .		0
482	An anti-CTLA-4 heavy chainâ€“only antibody with enhanced T _{reg} depletion shows excellent preclinical efficacy and safety profile. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	13
483	Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy. Cancers, 2022, 14, 4167.	1.7	6
484	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Frontiers in Oncology, 0, 12, .	1.3	5
485	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. Frontiers in Oncology, 0, 12, .	1.3	6
486	Human Lactoferrin Synergizes with Etoposide to Inhibit Lung Adenocarcinoma Cell Growth While Attenuating Etoposide-Mediated Cytotoxicity of Human Endothelial Cells. Biomedicines, 2022, 10, 2429.	1.4	0
488	Autoreactive napsin Aâ€“specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Science Immunology, 2022, 7, .	5.6	15
489	Is Melanoma Progression Affected by Thyroid Diseases?. International Journal of Molecular Sciences, 2022, 23, 10036.	1.8	3
490	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	5
491	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. Biomedicines, 2022, 10, 2211.	1.4	2
492	Circulating biomarkers of response to immunotherapy and immune-related adverse events. Expert Review of Molecular Diagnostics, 2022, 22, 855-865.	1.5	2
493	Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1â€“FGL1â€“MYH9 axis. Frontiers in Immunology, 0, 13, .	2.2	5
494	Cutaneous Reactions to Oncologic Immunotherapy. Updates in Clinical Dermatology, 2022, , 317-330.	0.1	0
495	Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy. Cancers, 2022, 14, 5121.	1.7	4

#	Article	IF	Citations
496	Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
497	The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation. Cancers, 2022, 14, 5374.	1.7	4
498	Using human genetics to improve safety assessment of therapeutics. Nature Reviews Drug Discovery, 2023, 22, 145-162.	21.5	20
499	Effectiveness of immunological agents in nonâ€small cell lung cancer. Cancer Reports, 2023, 6, .	0.6	3
501	NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Frontiers in Immunology, 0, 13, .	2.2	4
502	Molecular Events in the Melanogenesis Cascade as Novel Melanoma-Targeted Small Molecules: Principle and Development. Cancers, 2022, 14, 5588.	1.7	2
503	Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Seminars in Cancer Biology, 2023, 88, 81-95.	4.3	11
504	Immunotherapy and Endocrine Oncology. , 2022, , 1-36.		0
505	Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. Expert Opinion on Investigational Drugs, 2022, 31, 1151-1167.	1.9	3
506	Immune Checkpoint Inhibitor Therapy inÂOncology. JACC: CardioOncology, 2022, 4, 579-597.	1.7	25
507	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society. Endocrinology and Metabolism, 2022, 37, 839-850.	1.3	3
508	Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	12
509	Enhancing Natural Killer Cell Activity. , 2023, , 15-25.		2
510	Immune Checkpoint Inhibitors and Optic Neuropathy: A Systematic Review. Seminars in Ophthalmology, 2023, 38, 547-558.	0.8	1
511	[18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. , 2023, , 1-40.		0
512	A narrative review of the principal glucocorticoids employed in cancer. Seminars in Oncology, 2023, , .	0.8	0
513	Efficacy of ipilimumab 3Âmg/kg following progression on low-dose ipilimumab in metastatic melanoma. European Journal of Cancer, 2023, 186, 12-21.	1.3	0
514	Immunomodulatory Function of Interleukin-15 and Its Role in Exercise, Immunotherapy, and Cancer Outcomes. Medicine and Science in Sports and Exercise, 2023, 55, 558-568.	0.2	2

#	Article	IF	Citations
515	Immune Checkpoint Molecule TIGIT Regulates Kidney T Cell Functions and Contributes to AKI. Journal of the American Society of Nephrology: JASN, 2023, 34, 755-771.	3.0	6
516	The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis. Frontiers in Immunology, 0, 14, .	2.2	5
517	Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World Journal of Gastroenterology, 0, 29, 1054-1075.	1.4	18
518	Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis. World Journal of Gastrointestinal Oncology, 0, 15, 352-367.	0.8	0
519	Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events. Frontiers in Immunology, 0, 14, .	2.2	7
520	The Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy. Cancers, 2023, 15, 1300.	1.7	1
521	Assessment of Symptoms and Adverse Events Related to Immunotherapy in Patients With Cancer: An Integrative Review. Journal of Pain and Symptom Management, 2023, , .	0.6	0
522	Immunotherapies for advanced hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	4
523	The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress. Journal of Cellular Biochemistry, 2023, 124, 477-494.	1.2	4
524	Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics. Methods and Protocols, 2023, 6, 35.	0.9	3
525	Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies. Frontiers in Immunology, 0, 14, .	2.2	3
526	Inflammatory Muscle Diseases. , 2023, , 723-733.		0
527	Water-Soluble Au₂₅ Clusters with Single-Crystal Structure for Mitochondria-Targeting Radioimmunotherapy. ACS Nano, 2023, 17, 7837-7846.	7.3	11
528	Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World Journal of Gastrointestinal Oncology, 0, 15, 689-699.	0.8	1
529	Correction of endocrine complications of oncoimmunotherapy. Obesity and Metabolism, 2023, 19, 418-430.	0.4	0
540	Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib. Frontiers in Immunology, 0, 14, .	2.2	5
541	Advances in Therapeutic Targeting of the Tumor Necrosis Factor Receptor Superfamily Members for Cancer Immunotherapy. , 2023, , 1-73.		0
553	Immune Effects of Ablation. , 2023, , 1-17.		0

#	Article	IF	Citations
561	Immune Checkpoint Inhibition. , 2024, , 1-91.		0